have we found the panacea to covid-19 with remdesivir, an old but newly packaged drug. ¬© 2020, Royal College of Physicians of Edinburgh. All rights reserved.Investigators provided open-label remdesivir on a compassionate-use basis to patients hospitalised with severe COVID-19, an illness caused by infection with SARS-CoV-2. Severity was deÔ¨Å ned as an oxygen saturation of 94% or less while patients were breathing ambient air or receiving oxygen support. Patients with contraindications for remdesivir, including creatinine clearance below 30 ml/min and elevated liver enzymes beyond Ô¨Å ve times upper limit of normal, were excluded. Patients received a 10-day course of intravenous remdesivir, starting with loading dose of 200 mg administered intravenously on day one, followed by 100 mg daily for the remaining nine days.